In Vivo Endomicroscopic Description of Pulmonary Microcirculation in Systemic Sclerosis and Emphysema Patients (MiPECSE)

April 9, 2026 updated by: University Hospital, Rouen

Systemic sclerosis (SSc) is a generalized disorder of connective tissue, arterioles and microvessels, characterized by the occurrence of fibrosis and vascular obliteration phenomena. The alterations in lung microvessels are found in pulmonary involvement of scleroderma, which are the most serious complications of the disease.

In pulmonary emphysema, there are also changes in pulmonary microvasculature, which are involved in the onset and development of the disease.

The confocal endomicroscopy is an endoscopic technique which can be performed during a bronchoscopy. This technique makes it possible to observe in real time the most distal pulmonary elements at the microscopic scale. After injection of fluorescein, then the technique of observing the pulmonary microvasculature, in vivo and in situ.

The characterization of microvascular lesions in these two pathologies could improve understanding of their mechanisms and ultimately improve the early management of patients.

Study Overview

Study Type

Interventional

Enrollment (Actual)

9

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Rouen, France, 76031
        • Rouen University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with scleroderma with diffuse interstitial pneumonia, indicating a bronchoscopy.
  • Patients with pulmonary emphysema indication for bronchoscopy.
  • Age greater than 18 years.
  • Having an affiliation to social security.
  • Signed informed consent.

Exclusion Criteria:

  • Severe chronic respiratory insufficiency against-indicating the completion of a bronchoscopy
  • Hypercapnia defined by a PaCO2 ≥ 6 kPa
  • Disorders of hemostasis against-indicating performing a bronchoscopy
  • Anticoagulant therapy can not be interrupted time of completion of the examination
  • A history of pneumonectomy or contralateral exploration in a nonfunctional lung
  • Contraindication to the injection of fluorescein (including treatment with beta-blocker eye drops or po) or one of its excipients
  • History of an injection poorly tolerated fluorescein
  • A history of food allergy or drug known
  • Myocardial infarction <1 month
  • Unstable angina
  • Pregnant or lactating woman, premenopausal women without adequate contraception
  • Person under guardianship
  • Patient participating in another trial / participating in another trial within 4 weeks

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: patients with a suspicion of emphysema
A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of emphysema
A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
Experimental: patients with a suspicion of scleroderma
A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of sclerodermia
A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measurement of extra-alveolar diameter of capillaries of patient with pulmonary emphysema or pulmonary scleroderma
Time Frame: Day 1
Extra-alveolar diameter of capillaries is assessed using in vivo confocal endomicroscopy
Day 1
Measurement of intercapillary distance of patient with pulmonary emphysema or pulmonary scleroderma
Time Frame: Day 1
Intercapillary distance is assessed using in vivo confocal endomicroscopy
Day 1
Measurement of length of the capillary portions of patient with pulmonary emphysema or pulmonary scleroderma
Time Frame: Day 1
Length of the capillary is assessed using in vivo confocal endomicroscopy
Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measurement of alveolar diameter entries of patient with pulmonary emphysema or pulmonary scleroderma
Time Frame: Day 1
Alveolar diameter entries is assessed using in vivo confocal endomicroscopy
Day 1
Measurement of axial thickness of elastic fibers of patient with pulmonary emphysema or pulmonary scleroderma
Time Frame: Day 1
Axial thickness of elastic fibers is assessed using in vivo confocal endomicroscopy
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mathieu SALAUN, MD, University Hospital, Rouen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 24, 2014

Primary Completion (Actual)

May 7, 2018

Study Completion (Actual)

May 7, 2018

Study Registration Dates

First Submitted

September 17, 2015

First Submitted That Met QC Criteria

September 18, 2015

First Posted (Estimated)

September 22, 2015

Study Record Updates

Last Update Posted (Actual)

April 14, 2026

Last Update Submitted That Met QC Criteria

April 9, 2026

Last Verified

April 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Emphysema

Clinical Trials on Bronchoscopy with in vivo confocal endomicroscopy

Subscribe